

1 **The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing**
2 **on neutralization breadth against SARS-CoV-2 variants of concern**

3

4 Carl Graham^{1*}, Thomas Lechmere^{1*}, Aisha Rehman¹, Jeffrey Seow¹, Ashwini Kurshan¹,
5 Isabella Huettner¹, Thomas J.A. Maguire¹, Jerry Tam¹, Daniel Cox¹, Christopher Ward¹,
6 Mariusz Racz², Anele Waters², Christine Mant³, Michael H. Malim¹, Julie Fox¹, Katie J.
7 Doores^{1#}

8

9 ¹ Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's
10 College London, London, UK.

11 ² Harrison Wing, Guys and St Thomas' NHS Trust, London, UK.

12 ³ Infectious Diseases Biobank, Department of Infectious Diseases, School of Immunology
13 and Microbial Sciences, King's College London, London, UK.

14

15 * These authors contributed equally

16 # Corresponding author: katie.doores@kcl.ac.uk

17

18

19 **Abstract:**

20 COVID-19 vaccines are playing a vital role in controlling the COVID-19 pandemic. As
21 SARS-CoV-2 variants encoding mutations in the surface glycoprotein, Spike, continue to
22 emerge, there is increased need to identify immunogens and vaccination regimens that
23 provide the broadest and most durable immune responses. We compared the magnitude and
24 breadth of the neutralizing antibody response, as well as levels of Spike-reactive memory B
25 cells, in individuals receiving a second dose of BNT126b2 at a short (3-4 week) or extended
26 interval (8-12 weeks) and following a third vaccination approximately 6-8 months later. We
27 show that whilst an extended interval between the first two vaccinations can greatly increase
28 the breadth of the immune response and generate a higher proportion of Spike reactive
29 memory B cells, a third vaccination leads to similar levels between the two groups.
30 Furthermore, we show that the third vaccine dose enhances neutralization activity against
31 omicron lineage members BA.1, BA.2 and BA.4/BA.5 and this is further increased following
32 breakthrough infection during the UK omicron wave. These findings are relevant for
33 vaccination strategies in populations where COVID-19 vaccine coverage remains low.

34 **Introduction:**

35 Development of vaccines against SARS-CoV-2 has been a vital step in controlling the
36 global COVID-19 pandemic. Most approved vaccines use the SARS-CoV-2 Spike antigen to
37 elicit a neutralizing antibody response as well as generating cell-mediated immunity. The
38 Spike glycoprotein interacts with the angiotensin-converting enzyme 2 (ACE2) on host cells
39 and facilitates viral entry. One of the greatest challenges faced by current vaccines has been
40 the emergence of SARS-CoV-2 viral variants of concern (VOCs) that encode mutations in the
41 Spike protein, including alpha (B.1.1.7), beta (B.1.351), delta (B.1.617.2) and omicron (sub-
42 lineage members BA.1, BA.2, BA.4 and BA.5). Numerous studies have shown that these
43 Spike mutations can lead to partial escape in convalescent and vaccinee sera, with the
44 greatest reduction in neutralization being observed for omicron sub-lineages [1-5]. Therefore,
45 immunogens and immunization regimes that elicit durable neutralizing antibody (nAb)
46 responses with broad activity against both known and newly emerging variants is highly
47 desirable.

48 In December 2020, the Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine was
49 given approval for use in the UK. The approved regimen was two doses administered at a 3–
50 4-week interval, but in January 2021 a change to UK policy meant that the BNT162b2 booster
51 vaccination was administered with an extended interval of 8–12 weeks. The rationale behind
52 this change was to provide as much of the UK population with some level of immunity in the
53 face of a large wave of SARS-CoV-2 alpha variant infections [6]. Initially, most COVID-19
54 vaccines required two vaccinations to provide efficacy against the Wuhan (wild-type, WT)
55 alpha and delta VOCs. However, due to waning of vaccine-elicited nAb levels [7] and with the
56 emergence of omicron/BA.1, which encodes >30 mutations in Spike, a third vaccination (either
57 BNT162b2 or mRNA-1273) became recommended. A third vaccine has been shown to
58 increase neutralization titres against omicron/BA.1 [3-5, 8] and to restore vaccine efficacy
59 against omicron/BA.1 [9-11] however, breakthrough infections (BTI) in vaccinated individuals
60 have been observed at increased frequencies compared to previous dominant variants [9-11].

61 We sought to determine how the interval between the 1st and 2nd BNT162b2
62 vaccinations impacted on neutralization breadth and potency against current and newly
63 emerging VOCs in the short-term (post 2-doses) and in the long-term (post 3-doses), and how
64 subsequent BTI during the UK omicron wave (January to February 2022) affected
65 neutralization of newer omicron sub-lineage members. We show that broader plasma
66 neutralizing activity is observed when the 2nd dose is given with extended 8–12 week interval
67 (extended group) compared to those receiving the 2nd dose with a 3-4 week interval (short
68 group). However, the advantage of the extended booster to neutralization is not displayed
69 following a 3rd vaccination where robust neutralization of omicron lineages members (BA.1,
70 BA.2, BA.4 and BA.5) is observed in both groups. Finally, we show that omicron BTI further
71 boosts the neutralization activity against omicron sub-lineages. Overall, this research provides
72 insights into optimizing vaccine regimens to provide the greatest neutralization breadth.

73

74 **Results**

75 **Vaccine cohort description.**

76 Plasma and PBMCs were collected from individuals receiving the BNT162b2 vaccine
77 either with a short booster interval (3-4 weeks, n = 19, short-group) or an extended booster
78 interval (8-12 weeks, n = 28, extended-group) (**Figure 1A**). For the extended-group blood was
79 collected prior to vaccination (visit 1), 3 weeks post 1st dose (visit 2) and post 2nd dose (visit
80 3). For the short-group, blood was only collected post 2nd dose (visit 3). Blood was also
81 collected from both groups 6 months post 2nd vaccine dose (visit 4) and further samples was
82 taken 3-4 weeks and 6-months post 3rd vaccine (visit 5 and visit 6, respectively). For individuals
83 experiencing a BTI, blood was also collected post infection (visit 7).

84 The short-group was 84.2% female, with an average age of 44.1 years (interquartile
85 range, 15.0 years) whereas the extended-group was 53.6% female, with a slightly lower
86 average age of 38.0 years (interquartile range, 14.7 years) (**Figure 1B&C**). Information on
87 previous SARS-CoV-2 infection was recorded at each blood draw and the presence of IgG to
88 Nucleoprotein (N) was measured to determine previous asymptomatic SARS-CoV-2

89 infections or infections occurring prior to community PCR testing. Previous infection was
90 detected in 3/19 from the short-group and in 10/28 from the extended-group (**Figure 1D**). The
91 average interval between vaccine doses was 25.2 days (interquartile range, 3.5 days) for the
92 short group and 71.0 days (interquartile range, 11.3 days) in the extended group (**Figure 1E**).

93

94 **Anti-Spike IgG levels are similar in short and extended booster groups.**

95 IgG binding to recombinant Wuhan-1 Spike was measured by ELISA and the half-
96 maximal binding (ED_{50}) calculated (**Figure 2**). As reported previously [12-16], individuals who
97 had experienced a SARS-CoV-2 infection prior to vaccination had higher Spike IgG levels
98 compared to naïve individuals after the 1st vaccine dose (visit 2) (**Figure 2B**). However, similar
99 levels of anti-Spike IgG were observed in the SARS-CoV-2 naïve and convalescent donors
100 following the 2nd vaccination (visit 3) (**Figures 2A and 2B**).

101 For SARS-CoV-2 naïve individuals, comparison of ED_{50} between the short and
102 extended groups showed no statistical differences at visit 3, although there was a trend
103 towards higher levels in the extended group (**Figure 2C**). Both groups showed waning of the
104 anti-Spike IgG levels 6 months post 2nd vaccine (visit 4) which were subsequently boosted
105 after participants received a 3rd vaccine dose (visit 5) (**Figures 2A and 2B**).

106

107 **Previous SARS-CoV-2 infection leads to higher nAb titres following the first vaccine** 108 **dose.**

109 Next, plasma neutralization breadth and potency were determined using HIV-1
110 lentiviral particles pseudotyped with either the SARS-CoV-2 Spike of Wuhan-1 (vaccine
111 strain), alpha, delta, beta or omicron/BA.1 VOCs and a HeLa cell line stably expressing ACE2
112 as the target cell [17]. Analysis of neutralizing responses after a single vaccine dose (visit 2)
113 was only conducted on the extended-group due to sample availability (**Figure 1A**). Consistent
114 with previous studies [12-16], following 1-dose of BNT162b2, geometric mean titres (GMTs)
115 against the matched vaccine strain (Wuhan-1, wildtype, WT) were higher in those who had a

116 SARS-CoV-2 infection prior to vaccination (**Figures 3A-3C**). Furthermore, previously infected
117 individuals showed greater neutralization breadth against VOCs (**Figure 3A-3C**).

118

119 **An extended interval between the 2nd vaccine dose enhances the breadth of the**
120 **neutralizing antibody response.**

121 Following two doses of BNT162b2 in SARS-CoV-2 naïve individuals, GMTs against
122 the matched vaccine strain (Wuhan-1, WT) were similar between the short and extended
123 booster groups (**Figure 3D-3F**). In both the short and extended-groups, higher GMTs were
124 observed for individuals that had a SARS-CoV-2 infection prior to vaccination (**Figure 3G-3I**)
125 [12-16]. In SARS-CoV-2 naïve individuals (**Figures 3D and 3E**), the broadest neutralization
126 activity against VOCs was observed in the extended booster group where a modest 1.1–1.4-
127 fold reduction in neutralization was observed against alpha, delta, mu and beta and a 3.6-fold
128 reduction against omicron/BA.1 (**Figure 3E**). For those in the short-group, a larger reduction
129 in neutralization potency against VOCs was observed, with greater reductions against beta
130 (6.1-fold) and omicron (14.2-fold) (**Figure 3D**). Comparison between GMTs of the short and
131 extended booster groups showed a significantly reduced potency against mu, beta and
132 omicron/BA.1 VOCs in the short booster group (**Figure 3F**). Although overall GMTs against
133 VOCs were higher in previously infected vaccinees (**Figure 3G-3I**), the extended booster
134 group also showed higher GMTs against beta and omicron/BA.1 than the short booster group.
135 However, this difference did not reach significance due to the small sample size (**Figure 3I**).

136 To determine whether the extended booster generated neutralization breadth beyond
137 SARS-CoV-2 VOCs, neutralization was also measured against SARS-CoV-1 which shares
138 73% sequence [18] similarity with Spike of SARS-CoV-2. Although neutralization titres were
139 generally low, individuals receiving the extended booster showed low levels of SARS-CoV-1
140 neutralization (**Figure 3J**) with a GMT that was higher than in the short-group.

141

142 **An extended vaccine interval enhances the magnitude of the memory B cell response**

143 To further examine how vaccine interval impacts on the B cell response, we next
144 measured the frequencies of Spike-reactive memory B cells in the short and extended booster
145 groups using flow cytometry (**Figure 4A-B** and **Figure S1A**) [12, 19]. The frequency of Wuhan-
146 1 Spike-reactive memory B cells was measured in pre-vaccination samples (visit 1) for the
147 extended booster group only (due to sample availability) and in both groups following the 2nd
148 vaccination (visit 3). Overall, where paired samples were available, the overall frequency of
149 memory B cells did not change over the course of the analysis (**Figure S1B**). Participants who
150 had a SARS-CoV-2 infection prior to vaccination had a distinct population of Spike reactive
151 memory B cells in the pre-vaccine sample (mean 0.20 %, range 0.10 – 0.34%) compared to
152 naïve individuals (mean 0.02 %, range 0.01 – 0.06%) (**Figure 4C**). Following two vaccine
153 doses, the percentage of Spike-reactive memory B cells increased independent of prior
154 SARS-CoV-2 exposure (**Figure 4C**).

155 In SARS-CoV-2 naïve participants, a higher frequency of Spike reactive memory B
156 cells was observed in the extended booster group (mean 0.52 %, range 0.20 – 2.36%)
157 compared to the short booster group (mean 0.19 %, range 0.07 – 0.38%) after the 2nd vaccine
158 dose (**Figure 4C**). When considering the frequency of Spike-reactive B cells in previously
159 infected vaccinated donors, the percentage (mean 0.67 %, range 0.24 – 1.71 %) was similar
160 to SARS-CoV-2 naïve individuals in the extended group.

161 The isotype of the Spike-reactive memory B cells was considered further (**Figure 4D**).
162 In samples collected from previously infected individuals prior to vaccination, an average
163 64.5% of the Spike-reactive memory B cells were IgG positive (**Figure 4D**) and the average
164 percentage increased upon vaccination to 81.8% (**Figure 4D**) suggesting an improvement in
165 the quality of the response. In COVID-19 naïve individuals, a higher percentage of IgG+ Spike-
166 reactive memory B cells was seen in the extended-booster group (86.5%) compared to the
167 short-booster group (74.5%). A positive correlation between the percentage of Spike-reactive
168 memory B cells and the ED₅₀ and ID₅₀ (**Figures 4E and 4F**) was observed after two vaccine
169 doses independent of booster interval or previous SARS-CoV-2 exposure.

170 Overall, an extended period between the first and second vaccine dose increases the
171 magnitude of the Spike-specific B cell response.

172

173 **Neutralizing antibody levels decline at 6 months but are boosted and neutralization**
174 **broadened by a third vaccine dose.**

175 To understand the durability of the nAb response following two vaccine doses,
176 neutralization titres were measured 6 months post second vaccine dose (visit 4). Plasma
177 neutralization activity against all VOCs (WT, alpha, delta, beta and omicron (BA.1)) had
178 declined in both groups (**Figure 5A-D**) as reported in other recent studies [4, 8, 20]. Although
179 the neutralization of the most antigenically distant VOCs (beta and omicron/BA.1) had
180 declined, titres remained higher in the extended booster group compared to the short booster
181 group (**Figure 5A and 5B**).

182 In September 2021, a vaccine booster programme was initiated in the UK and blood
183 was collected from individuals 3-weeks after receiving a 3rd vaccine dose (visit 5). The impact
184 on IgG levels to Spike and neutralization breadth and potency was measured. The third
185 vaccine dose (visit 5) increased Spike IgG binding (**Figure 2**) and the plasma neutralizing
186 activity (**Figure 5A-D**) compared to visit 4 in both groups. Whereas after the second dose
187 there had been a clear distinction in neutralization breadth between the short and extended
188 booster groups, following administration of a third vaccine dose the neutralizing titres against
189 WT, alpha, delta, beta and omicron/BA.1 were very similar (**Figure 5A-D**). Importantly, a 3rd
190 vaccination with ancestral SARS-CoV-2 spike increased neutralization breadth against the
191 most highly diverse beta and omicron/BA.1 variants (**Figure 5C**). Overall, the reduced
192 neutralization breadth observed in the short booster group after two vaccine doses is rescued
193 following a third vaccine dose.

194

195 **Broader neutralization is associated with have higher avidity against Spike.**

196 Antibody binding avidity has been associated with antibody maturation [21-25]. To
197 determine whether enhanced neutralization breadth was related to higher avidity of antibody

198 binding in the extended booster group we next measured an avidity index for samples
199 collected 3-weeks and 6 months after the second vaccine dose (visit 3 and 4) and 3-weeks
200 after the third vaccine dose (visit 5). The avidity was measured by comparing the area under
201 the curve in ELISA, with and without an 8M Urea washing step. For SARS-CoV-2 naïve
202 individuals at visit 3, the extended booster group had a significantly higher avidity index than
203 the short booster group (**Figure 5E**). However, this difference was reduced in when comparing
204 previously infected individuals. The avidity index 6 months post 2nd vaccine (visit 4) was largely
205 unchanged (**Figure 5F**). Following the 3rd vaccination (visit 5) where neutralization breadth
206 was similar across the two groups, the avidity index increased in both groups and the
207 difference in avidity index between the short and extended groups was no longer significant
208 (**Figure 5G**). The avidity index 3-weeks after 2nd vaccine dose (visit 3) was correlated with the
209 ID₅₀ against each VOC (**Figure 5I**). No significant correlation was observed for WT. However,
210 the correlation coefficient was greatest for beta and omicron/BA.1 which are most antigenically
211 distant to the vaccine strain and suggests that avidity may be a good indicator VOC cross-
212 reactivity. The avidity index also correlated with the % of Spike-reactive memory B cells
213 (**Figure 5H**).

214

215 **Neutralization of BA.2 and BA.4/5 sub-lineages.**

216 Since omicron/BA.1 became the dominant global variant worldwide, several related
217 SARS-CoV-2 omicron sub-lineages have been reported that encode unique amino acid
218 changes in Spike. BA.2 has driven a recent wave in the UK and encodes 21 identical mutations
219 to BA.1 (including K417N, N440K and E484A) and 8 additional mutations across NTD and
220 RBD. BA.4 and BA.5, which encode identical Spikes proteins, are thought to be driving a 5th
221 wave in South Africa [26]. The BA.4/BA.5 Spike is similar to BA.2 but has additional mutations
222 delta69-70, L452R and F486V and lacks the Q493R mutation. Emergence of these highly
223 transmissible sub-lineages has led to an increased rate of breakthrough infections (BTIs) and,
224 within the cohort described here, fourteen participants experienced BTI between mid-
225 December 2021-March 2022. In mid-December BA.1 made up >80% of UK infections and the

226 BA.1 and BA.2 sub-lineages made up 95% of infections from mid-January [27]. Therefore,
227 BTIs in participants were presumed to be caused by BA.1 or BA.2 VOCs (visit 7). Blood was
228 also collected from six participants 6 months post 3rd dose (visit 6).

229 To assess susceptibility to the recently reported BA.4/BA.5 variants and to determine
230 the impact of BA.1/BA.2 BTI on the antibody response, we measured neutralization against
231 D614G, BA.1, BA.2 and BA.4/BA.5 following three BNT162b2 doses (at 3-weeks (visit 5) and
232 6-months (visit 6) post boost) and in those who subsequently experienced a BTI (3-weeks
233 post infection (visit 7)) (**Figure 6**). Due to the smaller number of samples available, all plasma
234 were considered together for analysis. For plasma collected 3-weeks post 3rd vaccine dose
235 (visit 5), good neutralization against BA.1, BA.2 and BA.4/5 was detected but GMTs were
236 slightly decreased compared to D614G, with the greatest reduction being 2.2-fold against
237 BA.4/5 (**Figure 6A**). Six months post 3rd vaccine dose (visit 6), neutralization titres had
238 decreased against all variants (**Figure 6B and 6D**) as seen six months post 2nd vaccine dose
239 (**Figure 5**). However, in those who experienced a BA.1/BA.2 BTI (visit 7) neutralization titres
240 increased against all variants compared to visit 5 and robust cross-neutralization of all omicron
241 sub-lineages was detected (**Figure 6C and 6E**). The largest fold increase in GMT following
242 BTI was observed against BA.1 and BA.2 (**Figure 6E**).

243 Overall, a third vaccine dose generates neutralization against omicron sub-lineages
244 BA.1, BA.2 and BA.4/5 which is further enhanced by BA.1/BA.2 BTI.

245

246 Discussion

247 Elicitation of nAbs with broad activity against both known and newly emerging variants
248 is highly desirable and vital in controlling the current COVID-19 pandemic. Here we studied
249 the impact of vaccine interval on the breadth and potency of the SARS-CoV-2 neutralizing
250 antibody response. We showed that an extended interval between the 1st and 2nd dose of the
251 BNT162b2 vaccine enhances neutralization breadth initially. However, a third vaccine dose
252 generated a robust and broad neutralizing response against VOCs independent of the interval
253 between 1st and 2nd vaccine doses. It has been extensively reported that ‘hybrid’ immunity,

254 immunity derived from SARS-CoV-2 infection followed by vaccination, leads to superior
255 neutralization following 1-dose of COVID-19 vaccine [12-16]. Our results showing higher
256 antibody binding and neutralization in previously infected individuals receiving one BNT162b2
257 dose are consistent with these reports.

258 Here, we show that an extended interval between the 1st and 2nd vaccine dose
259 enhances the immune response in four ways. Firstly, and similar to previous reports, there is
260 an increase in IgG binding (ED₅₀) to Spike in the extended booster group following the 2nd
261 immunization [23, 28, 29] and secondly, the Spike-reactive IgG bind with higher avidity [23].
262 Thirdly, broader neutralizing activity against VOCs (including BA.1) is generated [30, 31].
263 Finally, a higher percentage of Spike-reactive IgG⁺ memory B cells is detected in SARS-CoV-
264 2 naïve individuals receiving an extended booster. Binding avidity correlated most strongly
265 with the ID₅₀ against the most antigenically distinct VOCs. The higher binding avidity in the
266 extended group suggests that antibodies have undergone higher levels of antibody maturation
267 [21-24]. Indeed, wider SARS-CoV-2 neutralization breadth has been associated with
268 increased somatic hypermutation [12, 32-34]. We have recently reported that mAbs isolated
269 from an individual receiving 2-doses of the ChadOx1 AZD1222 vaccine at a 12-week interval
270 were more highly mutated than those isolated from SARS-CoV-2 convalescent donors and
271 displayed greater neutralization breadth [32]. Several studies have shown that mRNA
272 vaccination leads to a robust memory B cell response and induces persistent germinal centre
273 reactions that continue for months after primary vaccination [12, 19, 35, 36]. Therefore, a
274 longer interval between the 1st and 2nd vaccine dose would allow extended germinal centre
275 reactions to take place, leading to increased levels of somatic hypermutation and higher
276 affinity to vaccine antigen.

277 Neutralization titres decreased 6 months post 2nd vaccine dose [20]. However,
278 consistent with previous research, we show that titres are boosted following the 3rd BNT162b2
279 vaccination. Importantly, neutralization breadth increased against beta and omicron sub-
280 lineages independent of the interval between the 1st and 2nd vaccine doses leading to overall
281 similar levels of cross-neutralizing activity in both the short and extended booster groups. This

282 increase in neutralization breadth was accompanied by an increase in the Spike-reactive IgG
283 binding avidity in the short booster group, indicative of continued affinity maturation.
284 Nussenzweig and co-workers identified antibody lineages that had undergone further somatic
285 hypermutation following a 3rd dose of COVID-19 mRNA vaccine and these mAbs had superior
286 neutralization breadth and potency [37]. Relevant to the COVID-19 pandemic at the time of
287 writing (June 2022), neutralization against the antigenically distant VOCs BA.1 [3-5, 8], BA.2
288 [2, 38, 39] and BA.4/BA.5 [40-42] also increased following a 3rd vaccine dose in both groups.

289 Following BTI during the UK BA.1 or BA.2 wave, neutralization titres against D614G,
290 BA.1, BA.2 and BA.4/BA.5 increased in this cohort independent of previous SARS-CoV-2
291 infection. The fold increases in GMT were larger against Omicron sub-lineages compared to
292 against D614G. Increases in omicron sub-lineage neutralization following omicron BTI has
293 been observed in other cohorts [43-45]. Furthermore, boosting mRNA vaccinated mice with
294 an omicron/BA.1 based mRNA vaccine increased serum neutralization activity and protection
295 against omicron/BA.1 [46]. Recent studies indicate that the increase in cross-neutralizing
296 activity is mostly driven by re-activation of B cell clones initially generated through vaccination
297 with Wuhan-1 Spike that cross-react with the VOC, with little evidence of the generation of a
298 *de novo* VOC-specific antibody response [44, 47, 48]. These observations are contradictory
299 to recent reports suggesting that antibody responses to omicron/BA.1 were limited following
300 an omicron BTI in triple vaccinated donors who had been infected prior to vaccination [49].

301 The findings of this study are applicable in populations where COVID-19 vaccine
302 coverage remains low and where there is limited vaccine supply. In vaccine naïve populations,
303 an extended interval will likely be beneficial through generation of broader antibody-based
304 immunity against VOCs in the first six months following the 2nd vaccine dose. Indeed, vaccine
305 effectiveness was shown to be significantly higher in those receiving a longer interval between
306 mRNA doses [50, 51]. However, whilst there is broader activity following the 2nd vaccine dose
307 in the extended group, there would be a longer period following the 1st vaccine in which
308 antibody titres will remain low and narrow which in turn may lead to a higher risk of infection
309 during this period. Importantly, despite the interval between the 1st and 2nd vaccine doses, a

310 third vaccine dose increases neutralization against the current VOCs including omicron sub-
311 lineages BA.1, BA.2, BA.4 and BA.5.

312 In summary, in a SARS-CoV-2 naïve population, an extended interval between the 1st
313 and 2nd doses of BNT162b2 leads to an increased neutralization breadth, Spike binding avidity
314 and frequency of Spike-reactive memory B cells. However, this advantage is lost when a 3rd
315 vaccine dose is administered 6-8 months later where broad neutralization against current
316 omicron sub-lineages is observed in both groups. These findings provide insights into
317 optimizing vaccine regimens to provide the greatest neutralization breadth.

318

319 **Limitations of the study**

320 A limitation of this study is the relatively small sample size in each group which limits
321 the power of the statistical analysis. The impact on cell-mediated immune responses has not
322 been investigated. However, Hall *et al* have previously show that no significant differences in
323 Spike-specific polyfunctional CD4+ T cell responses between the short and extended groups
324 [52] whereas Payne et al reported higher levels of these cells in the extended group [28]. This
325 study does not assess whether the broader neutralization response in the extended-group
326 reduced breakthrough infections.

327

328 **Materials and Methods:**

329

330 **Ethics.** This study used human samples collected with written consent as part of a study
331 entitled “Antibody responses following COVID-19 vaccination”. Ethical approval was obtained
332 from the King’s College London Infectious Diseases Biobank (IBD) (KDJF-110121) under the
333 terms of the IBD’s ethics permission (REC reference: 19/SC/0232) granted by the South
334 Central – Hampshire B Research Ethics Committee in 2019.

335

336 **Protein expression and purification.**

337 Recombinant Spike and nucleoprotein for ELISA were expressed and purified as
338 previously described [17, 53].

339

340 **ELISA (Spike and nucleoprotein).**

341 96-well plates (Corning, 3690) were coated with antigen at 3 µg/mL overnight at 4°C.
342 The plates were washed (5 times with PBS/0.05% Tween-20, PBS-T), blocked with blocking
343 buffer (5% skimmed milk in PBS-T) for 1 h at room temperature. Serial dilutions of plasma in
344 blocking buffer were added and incubated for 2 hr at room temperature. Plates were washed
345 (5 times with PBS-T) and secondary antibody was added and incubated for 1 hr at room
346 temperature. IgG was detected using Goat-anti-human-Fc-AP (alkaline phosphatase)
347 (1:1,000) (Jackson: 109-055-098). Plates were washed (5 times with PBS-T) and developed
348 with AP substrate (Sigma) and read at 405 nm.

349

350 **Avidity ELISA**

351 The ELISA was carried out as described above. A 4-point titration (starting at 1:25, 1:4 dilution
352 series) was used. After incubation of plasma, one half of the plate was incubated with 8M Urea
353 and the other half incubated with PBS for 10mins before washing 5-time with PBS-T. The area
354 under the curve was determined in Prism (Log dilution). The avidity index was calculated using
355 the following formula:

$$356 \text{ Avidity index} = 100 * \left(\frac{\text{Area under curve with 8M Urea}}{\text{Area under curve with no Urea}} \right)$$

357

358 **Neutralisation assay with SARS-CoV-2 pseudotyped virus**

359 Pseudotyped HIV-1 virus incorporating the SARS-CoV-2 Spike protein (either wuhan-1,
360 D614G, alpha (B.1.1.7), beta (B.1.351), delta (B.1.671.2), mu (B.1.621), omicron (BA.1, BA.2
361 or BA.4/5) were prepared as previously described [17, 54]. Viral particles were produced in a
362 10 cm dish seeded the day prior with 5×10^6 HEK293T/17 cells in 10 ml of complete Dulbecco's
363 Modified Eagle's Medium (DMEM-C, 10% FBS and 1% Pen/Strep) containing 10% (vol/vol)

364 foetal bovine serum (FBS), 100 IU/ml penicillin and 100 µg/ml streptomycin. Cells were
365 transfected using 90 µg of PEI-Max (1 mg/mL, Polysciences) with: 15µg of HIV-luciferase
366 plasmid, 10 µg of HIV 8.91 gag/pol plasmid and 5 µg of SARS-CoV-2 spike protein plasmid
367 [55, 56]. The supernatant was harvested 72 hours post-transfection. Pseudotyped virus
368 particles was filtered through a 0.45µm filter, and stored at -80°C until required.

369 Serial dilutions of plasma samples (heat inactivated at 56°C for 30mins) were prepared with
370 DMEM media (25µL) (10% FBS and 1% Pen/Strep) and incubated with pseudotyped virus
371 (25µL) for 1-hour at 37°C in half-area 96-well plates. Next, Hela cells stably expressing the
372 ACE2 receptor were added (10,000 cells/25µL per well) and the plates were left for 72 hours.
373 Infection levels were assessed in lysed cells with the Bright-Glo luciferase kit (Promega), using
374 a Victor™ X3 multilabel reader (Perkin Elmer). Each serum sample was run in duplicate and
375 was measured against the five SARS-CoV-2 variants within the same experiment using the
376 same dilution series.

377 **FACS analysis of Spike-specific memory B cells.**

378 Flow cytometry of cryopreserved PBMCs was performed on a BD FACS Melody as previously
379 described. SARS-CoV-2 Wuhan-1 Spike was pre-complexed with the streptavidin fluorophore
380 (Alexa-488) at a 4:1 molar ratio prior to addition to cells. PBMCs were incubated with Fc block
381 for 15 minutes at 4°C. PBMCs were stained with anti-CD3-BV510 (Biolegend), anti-CD19-
382 PerCP-Cy5.5 (Biolegend), anti-IgD-Pacific Blue (Biolegend), anti-CD27-BV785 (Biolegend),
383 anti-CD38-APC-Cy7 (Biolegend), anti-CD20-APC (Biolegend), anti-IgG-PE-Cy7 (BD
384 Biosciences), anti-IgM-PE (Biolegend) and Spike-Alexa Fluor 488 for 1 hour at 4°C. PBMCs
385 were washed with PBS and stained with live/dead for 1 hour at 4°C.

386

387

388 **Figures and legends:**

389

390 **Figure 1: A)** Vaccination and blood sampling schedule in short and extended vaccine groups.


391 Horizontal line shows the mean age for each group. **B)** Difference in age between short- and

392 extended-groups. **C)** Gender of participants in each group. **D)** Frequency of previous SARS-

393 CoV-2 infection. **E)** Length of time between the 1st and 2nd dose of BNT162b2 vaccine.

394 Horizontal line shows the mean days between vaccine doses. Short- and extended-groups


395 shown in circle and triangles, respectively.



396

397

398 **Figure 2: IgG binding titres to SARS-CoV-2 Spike over time. A)** Comparison of geometric
399 mean ED₅₀ values between SARS-CoV-2 naïve individuals (open black circle) and those
400 previously infected before vaccination (grey/red circles) in short-booster group. **B)**
401 Comparison of geometric mean ED₅₀ values between SARS-CoV-2 naïve individuals (open
402 black triangle) and those previously infected before vaccination (grey/red triangle) in
403 extended-booster group. **C)** Comparison of geometric mean ED₅₀ values between short- and
404 extended-booster groups at visit 3, 4 and 5. Dotted line represents the lowest limit of detection
405 for the assay. D'Agostino and Pearson tests were performed to determine normality. Based
406 on this result, multiple Mann-Whitney tests or unpaired t tests using a two-stage linear step-
407 up procedure of Benjamini, Krieger and Yekutieli were employed to determine significance
408 between groups. ns P > 0.05, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 and **** P ≤ 0.0001.




409

410

411

412 **Figure 3: Neutralization breadth and potency following two-doses of BNT162b2.**
413 Neutralization was measured against wuhan-1 (WT), alpha, delta, mu, beta and omicron/BA.1.
414 **A)** Neutralization following a single BNT162b2 vaccine dose (visit 2) in naïve individuals (n =
415 18). **B)** Neutralization following a single BNT162b2 vaccine dose in individuals infected with
416 SARS-CoV-2 prior to vaccination (n = 10). Data from individual donors are linked and fold
417 changes compared to WT shown above. **C)** GMT comparison between SARS-CoV-2 naïve
418 individuals (open triangle) and convalescent donors (grey triangle) following one vaccine dose.
419 The horizontal line shows the GMT. Neutralization data following 2-vaccine doses (visit 3) in
420 SARS-CoV-2 naïve individuals in **D)** the short booster group (n = 16), and **E)** the extended
421 booster group (n = 18). Data from individual donors are linked and fold changes compared to
422 WT shown above. **F)** GMT comparison in SARS-CoV-2 naïve individuals receiving the short
423 booster interval (open circle) and extended booster (open triangle). The horizontal line shows
424 the GMT. Neutralization data following 2-vaccine doses (visit 3) in SARS-CoV-2 convalescent
425 individuals in **G)** the short booster group (n = 3) and **H)** the extended booster group (n = 9).
426 Data from individual donors are linked and fold changes compared to WT shown above. **I)**
427 GMT comparison in SARS-CoV-2 convalescent individuals receiving the short booster interval
428 (grey circle) and extended booster (grey triangle). The horizontal line shows the GMT. **J)**
429 Neutralization of SARS-CoV-1. The horizontal dotted line is the lowest limit of detection.
430 D'Agostino and Pearson tests were performed to determine normality. Based on this result,
431 multiple Mann-Whitney tests using a two-stage linear step-up procedure of Benjamini, Krieger
432 and Yekutieli were employed to determine significance between groups. ns $P > 0.05$, * $P \leq$
433 0.05 , ** $P \leq 0.01$, *** $P \leq 0.001$ and **** $P \leq 0.0001$.
434




435
436

437

438 **Figure 4. Higher percentage of SARS-CoV-2 Spike-reactive memory B cells are detected**
439 **in the extended booster group.** Percentage of Spike-reactive memory B cells were
440 determined by flow cytometry. **A)** Example pre-bleed (visit 1) PBMC staining for SARS-CoV-
441 2 naïve individual. **B)** Example visit 3 PBMC staining for SARS-CoV-2 naïve individual.
442 Example of full flow analysis shown in **Figure S1A**. **C)** Percentage Spike-reactive memory B
443 cells at visit 1 and visit 3 were determined by flow cytometry. Previously infected individuals
444 shown in red/grey. Extended and short interval groups shown with triangle and circle symbols,
445 respectively. D'Agostino and Pearson tests were performed to determine normality. Based on
446 this result, differences between groups were assessed using a Brown-Forsythe ANOVA test
447 with Dunnett's T3 multiple comparisons post hoc. ns $P > 0.05$, * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq$
448 0.001 and **** $P \leq 0.0001$. **D)** Percentage of IgG, IgM or other Spike-reactive memory B cells
449 for each vaccine group. **E)** Correlation between Spike IgG ED_{50} and percentage of Spike-
450 reactive memory B cells. **F)** Correlation between ID_{50} against Wuhan-1 pseudotyped virus and
451 percentage of Spike-reactive memory B cells. (Spearman's correlation, r ; a linear regression
452 was used to calculate the goodness of fit, r^2).

453




454

455


456

457 **Figure 5. Neutralization potency decreases 6-months post 2nd vaccine but breadth and**
458 **potency increase after a 3rd vaccine dose.** Neutralization ID₅₀ against WT, alpha, delta, beta
459 and omicron/BA.1 at visits 3, 4 and 5 in the **A)** short (circle) and **B)** extended (triangle) booster
460 groups for SARS-CoV-2 naïve individuals and **C)** short (grey circle) and **D)** extended (grey
461 triangle) booster groups previously infected individuals. Difference between GMT at visits 3,
462 4 and 5 were determined using Mann-Whitney unpaired t-test. D'Agostino and Pearson tests
463 were performed to determine normality. Based on this result, differences between groups were
464 assessed using either one-way ANOVA (Tukey's multiple comparisons post hoc), Kruskal-
465 Wallis test (Dunn's multiple comparisons post hoc) or Friedman test (Dunn's multiple
466 comparisons post hoc). ns $P > 0.05$, * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$ and **** $P \leq 0.0001$.
467 Avidity index for IgG binding to Spike was measured at **E)** visit 3, **F)** visit 4 and **G)** visit 5 and
468 compared across groups. Avidity index was calculated by comparing the area under the curve
469 (AUC) with/without an 8M Urea washing step. D'Agostino and Pearson tests were performed
470 to determine normality. Based on this result, differences between groups were assessed using
471 a Kruskal-Wallis test with Dunn's multiple comparisons post hoc. **H)** Correlations between
472 avidity index and ID₅₀ against VOCs following 2-doses of BNT162b2 vaccine. **I)** Correlation
473 between avidity index and % Spike-reactive memory B cells. (Spearman's correlation, r ; a
474 linear regression was used to calculate the goodness of fit, r^2).



475

476 **Figure 6: Neutralization against omicron sub-lineages following 3 vaccine doses**
477 **and/or BA.1/BA.2 breakthrough infection.** Neutralization breadth and potency was
478 measured against D614G, BA.1, BA.2 and BA.4/BA.5. Analysis of sera collected **A)** 3-weeks
479 post 3rd BNT162b2 vaccine dose (visit 5), **B)** 6-months post 3rd vaccine (visit 6) and **C)**
480 following breakthrough infection (visit 7) (presumed to be BA.1 or BA.2). **D)** Comparison of
481 titres 3-weeks (visit 5) and 6-months post 3rd boost (visit 6). **E)** Comparison of titres 3-weeks
482 post 3rd boost (visit 5) and following BTI (visit 7). Samples from a single individual are joined.
483 Short and long booster groups shown with circle and triangle symbols, respectively.
484 Individuals infected with SARS-CoV-2 prior to vaccination are shaded grey. Based on this
485 result, multiple Mann-Whitney tests or unpaired t tests using a two-stage linear step-up
486 procedure of Benjamini, Krieger and Yekutieli were employed to determine significance
487 between groups. ns $P > 0.05$, * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$ and **** $P \leq 0.0001$.



488

489 **Acknowledgements**

490 We thank Philip Brouwer, Marit van Gils and Rogier Sanders for the Spike protein construct,
491 Leo James and Jakub Luptak for the N protein, Wendy Barclay for providing the B.1.617.2,
492 BA.1, BA.2 and BA.4/BA.5 Spike plasmids and James Voss and Deli Huang for providing the
493 Hela-ACE2 cells.

494

495 **Funding**

496 This work was funded by; Huo Family Foundation Award to MHM and KJD, MRC Genotype-
497 to-Phenotype UK National Virology Consortium ([MR/W005611/1] to MHM and KJD),
498 Fondation Dormeur, Vaduz for funding equipment to KJD, Wellcome Trust Investigator Award
499 [222433/Z/21/Z] to MHM, and Wellcome Trust Multi-User Equipment Grant [208354/Z/17/Z]
500 to MHM. and KJD. CG was supported by the MRC-KCL Doctoral Training Partnership in
501 Biomedical Sciences [MR/N013700/1]. DC was supported by a BBSRC CASE in partnership
502 with GlaxoSmithKline [BB/V509632/1]. This work and the Infectious Diseases Biobank (CM)
503 were supported by the Department of Health via a National Institute for Health Research
504 comprehensive Biomedical Research Centre award to Guy's and St Thomas' NHS Foundation
505 Trust in partnership with King's College London and King's College Hospital NHS Foundation
506 Trust. This study is part of the EDCTP2 programme supported by the European Union (grant
507 number RIA2020EF-3008 COVAB) (KJD, JF, MHM). The views and opinions of authors
508 expressed herein do not necessarily state or reflect those of EDCTP. This project is supported
509 by a joint initiative between the Botnar Research Centre for Child Health and the European &
510 Developing Countries Clinical Trials Partnership (KJD and JF).

511

512 **References**

- 513 1. Lechmere T, Snell LB, Graham C, Seow J, Shalim ZA, Charalampous T, et al. Broad
514 Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection
515 with Delta in COVID-19-Vaccinated Individuals. *mBio*. 2022:e0379821. Epub 2022/03/18. doi:
516 10.1128/mbio.03798-21. PubMed PMID: 35297676.
- 517 2. Arora P, Zhang L, Rocha C, Sidarovich A, Kempf A, Schulz S, et al. Comparable
518 neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3. *Lancet Infect*

- 519 Dis. 2022. Epub 2022/04/16. doi: 10.1016/S1473-3099(22)00224-9. PubMed PMID:
520 35427493; PubMed Central PMCID: PMCPMC9005119 grant numbers 01KI2006D,
521 01KI20328A, 01KX2021), the Ministry for Science and Culture of Lower Saxony (grant
522 numbers 14-76103-184, MWK HZI COVID-19), and the German Research Foundation (DFG;
523 grant numbers PO 716/11-1, PO 716/14-1). MSW received unrestricted funding from
524 Sartorius, Lung research. H-MJ received funding from BMBF (grant numbers 01KI2043,
525 NaFoUniMedCovid19-COVIM 01KX2021), Bavarian State Ministry for Science and the Arts,
526 and DFG through the research training groups RTG1660 and TRR130, the Bayerische
527 Forschungsstiftung (Project CORAd), and the Kastner Foundation. GMNB acknowledges
528 funding from the German Center for Infection Research (grant number 80018019238) and a
529 European Regional Development Fund (Defeat Corona, grant number ZW7-8515131,
530 together with AD-J). All other authors declare no competing interests.
- 531 3. Doria-Rose NA. Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape
532 from Neutralizing Antibodies. medRxiv. 2021. doi: 10.1101/2021.12.15.21267805.
- 533 4. Gruell H, Vanshylla K, Tober-Lau P, Hillus D, Schommers P, Lehmann C, et al. mRNA
534 booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2
535 Omicron variant. *Nat Med.* 2022;28(3):477-80. Epub 2022/01/21. doi: 10.1038/s41591-021-
536 01676-0. PubMed PMID: 35046572; PubMed Central PMCID: PMCPMC8767537.
- 537 5. Wu M, Wall EC, Carr EJ, Harvey R, Townsley H, Mears HV, et al. Three-dose vaccination
538 elicits neutralising antibodies against omicron. *Lancet.* 2022. Epub 2022/01/23. doi:
539 10.1016/S0140-6736(22)00092-7. PubMed PMID: 35065005; PubMed Central PMCID:
540 PMCPMC8769665.
- 541 6. UK DoHaSC. Optimising the COVID-19 vaccination programme for maximum short-
542 term impact. 2021.
- 543 7. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, et al.
544 Waning Immunity after the BNT162b2 Vaccine in Israel. *N Engl J Med.* 2021;385(24):e85. Epub
545 2021/10/28. doi: 10.1056/NEJMoa2114228. PubMed PMID: 34706170; PubMed Central
546 PMCID: PMCPMC8609604.
- 547 8. Goel RR, Painter MM, Lundgreen KA, Apostolidis SA, Baxter AE, Giles JR, et al. Efficient
548 recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. *Cell.*
549 2022. Epub 2022/05/07. doi: 10.1016/j.cell.2022.04.009. PubMed PMID: 35523182; PubMed
550 Central PMCID: PMCPMC8989683.
- 551 9. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, AlMukdad S, Yassine HM, Al-Khatib HA, et
552 al. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. *N Engl J*
553 *Med.* 2022;386(19):1804-16. Epub 2022/03/10. doi: 10.1056/NEJMoa2200797. PubMed
554 PMID: 35263534; PubMed Central PMCID: PMCPMC8929389.
- 555 10. Andrews N, Stowe J, Kirsebom F, Toffa S, Ricketts T, Gallagher E, et al. Covid-19
556 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. *N Engl J Med.*
557 2022;386(16):1532-46. Epub 2022/03/07. doi: 10.1056/NEJMoa2119451. PubMed PMID:
558 35249272; PubMed Central PMCID: PMCPMC8908811.
- 559 11. Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, et al. Association
560 Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-
561 CoV-2 Omicron and Delta Variants. *JAMA.* 2022;327(7):639-51. Epub 2022/01/22. doi:
562 10.1001/jama.2022.0470. PubMed PMID: 35060999; PubMed Central PMCID:
563 PMCPMC8848203.
- 564 12. Goel RR, Apostolidis SA, Painter MM, Mathew D, Pattekar A, Kuthuru O, et al. Distinct
565 antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals

- 566 following mRNA vaccination. *Sci Immunol.* 2021;6(58). Epub 2021/04/17. doi:
567 10.1126/sciimmunol.abi6950. PubMed PMID: 33858945; PubMed Central PMCID:
568 PMCPMC8158969.
- 569 13. Manisty C, Otter AD, Treibel TA, McKnight A, Altmann DM, Brooks T, et al. Antibody
570 response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. *Lancet.*
571 2021;397(10279):1057-8. Epub 2021/03/01. doi: 10.1016/S0140-6736(21)00501-8. PubMed
572 PMID: 33640038; PubMed Central PMCID: PMCPMC7972310.
- 573 14. Stamatatos L, Czartoski J, Wan YH, Homad LJ, Rubin V, Glantz H, et al. mRNA
574 vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection.
575 *Science.* 2021. Epub 2021/03/27. doi: 10.1126/science.abg9175. PubMed PMID: 33766944;
576 PubMed Central PMCID: PMCPMC8139425.
- 577 15. Reynolds CJ, Pade C, Gibbons JM, Butler DK, Otter AD, Menacho K, et al. Prior SARS-
578 CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. *Science.*
579 2021. Epub 2021/05/02. doi: 10.1126/science.abh1282. PubMed PMID: 33931567; PubMed
580 Central PMCID: PMCPMC8168614.
- 581 16. Saadat S, Rikhtegaran Tehrani Z, Logue J, Newman M, Frieman MB, Harris AD, et al.
582 Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers
583 Previously Infected With SARS-CoV-2. *JAMA.* 2021;325(14):1467-9. Epub 2021/03/02. doi:
584 10.1001/jama.2021.3341. PubMed PMID: 33646292; PubMed Central PMCID:
585 PMCPMC7922233.
- 586 17. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal
587 observation and decline of neutralizing antibody responses in the three months following
588 SARS-CoV-2 infection in humans. *Nat Microbiol.* 2020;5(12):1598-607. Epub 2020/10/28. doi:
589 10.1038/s41564-020-00813-8. PubMed PMID: 33106674.
- 590 18. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Velesler D. Structure, Function,
591 and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell.* 2020;183(6):1735. Epub
592 2020/12/12. doi: 10.1016/j.cell.2020.11.032. PubMed PMID: 33306958.
- 593 19. Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, et al. mRNA
594 Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to
595 Variants of Concern. *bioRxiv.* 2021. Epub 2021/09/01. doi: 10.1101/2021.08.23.457229.
596 PubMed PMID: 34462751; PubMed Central PMCID: PMCPMC8404899.
- 597 20. Evans JP, Zeng C, Carlin C, Lozanski G, Saif LJ, Oltz EM, et al. Neutralizing antibody
598 responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by
599 breakthrough infection. *Sci Transl Med.* 2022;14(637):eabn8057. Epub 2022/02/16. doi:
600 10.1126/scitranslmed.abn8057. PubMed PMID: 35166573; PubMed Central PMCID:
601 PMCPMC8939766.
- 602 21. Liu H, Wu NC, Yuan M, Bangaru S, Torres JL, Caniels TG, et al. Cross-Neutralization of
603 a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. *Immunity.*
604 2020;53(6):1272-80 e5. Epub 2020/11/27. doi: 10.1016/j.immuni.2020.10.023. PubMed
605 PMID: 33242394; PubMed Central PMCID: PMCPMC7687367 COVA1-16 and other antibodies
606 first disclosed by Brouwer et al. (2020) has been filed by Amsterdam UMC under application
607 number 2020-039EP-PR. I.A.W. is a member of the Immunity Editorial Board.
- 608 22. Rudnick SI, Adams GP. Affinity and avidity in antibody-based tumor targeting. *Cancer*
609 *Biother Radiopharm.* 2009;24(2):155-61. Epub 2009/05/05. doi: 10.1089/cbr.2009.0627.
610 PubMed PMID: 19409036; PubMed Central PMCID: PMCPMC2902227.
- 611 23. Tauzin A, Gong SY, Beaudoin-Bussieres G, Vezina D, Gasser R, Nault L, et al. Strong
612 humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination

- 613 with a 16-week interval between doses. *Cell Host Microbe*. 2022;30(1):97-109 e5. Epub
614 2021/12/27. doi: 10.1016/j.chom.2021.12.004. PubMed PMID: 34953513; PubMed Central
615 PMCID: PMC8639412.
- 616 24. Young C, Brink R. The unique biology of germinal center B cells. *Immunity*.
617 2021;54(8):1652-64. Epub 2021/08/12. doi: 10.1016/j.immuni.2021.07.015. PubMed PMID:
618 34380063.
- 619 25. Bjorkman C, Naslund K, Stenlund S, Maley SW, Buxton D, Uggla A. An IgG avidity ELISA
620 to discriminate between recent and chronic *Neospora caninum* infection. *J Vet Diagn Invest*.
621 1999;11(1):41-4. Epub 1999/01/30. doi: 10.1177/104063879901100106. PubMed PMID:
622 9925210.
- 623 26. Tegally H. Continued Emergence and Evolution of Omicron in South Africa: New BA.4
624 and BA.5 lineages. *medRxiv*. 2022. doi: 10.1101/2022.05.01.22274406.
- 625 27. Briefing T. 2022.
- 626 28. Payne RP, Longet S, Austin JA, Skelly DT, Dejnirattisai W, Adele S, et al. Immunogenicity
627 of standard and extended dosing intervals of BNT162b2 mRNA vaccine. *Cell*.
628 2021;184(23):5699-714 e11. Epub 2021/11/05. doi: 10.1016/j.cell.2021.10.011. PubMed
629 PMID: 34735795; PubMed Central PMCID: PMC8519781.
- 630 29. Parry H, Bruton R, Stephens C, Bentley C, Brown K, Amirthalingam G, et al. Extended
631 interval BNT162b2 vaccination enhances peak antibody generation. *NPJ Vaccines*.
632 2022;7(1):14. Epub 2022/01/29. doi: 10.1038/s41541-022-00432-w. PubMed PMID:
633 35087066; PubMed Central PMCID: PMC8795435.
- 634 30. Belik M, Jalkanen P, Lundberg R, Reinholm A, Laine L, Vaisanen E, et al. Comparative
635 analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing
636 antibodies against Delta and Omicron variants. *Nat Commun*. 2022;13(1):2476. Epub
637 2022/05/06. doi: 10.1038/s41467-022-30162-5. PubMed PMID: 35513437; PubMed Central
638 PMCID: PMC9072399.
- 639 31. Chatterjee D, Tauzin A, Marchitto L, Gong SY, Boutin M, Bourassa C, et al. SARS-CoV-2
640 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination
641 with a 16-week interval between doses. *Cell Rep*. 2022;38(9):110429. Epub 2022/02/27. doi:
642 10.1016/j.celrep.2022.110429. PubMed PMID: 35216664; PubMed Central PMCID:
643 PMC8823958.
- 644 32. Seow J, Graham C, Hallett SR, Lechmere T, Maguire TJA, Huettner I, et al. ChAdOx1
645 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-
646 CoV-2 viral variants. *Cell Rep*. 2022;110757. Epub 2022/04/28. doi:
647 10.1016/j.celrep.2022.110757. PubMed PMID: 35477023; PubMed Central PMCID:
648 PMC9010245.
- 649 33. Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of
650 antibody immunity to SARS-CoV-2. *Nature*. 2021;591(7851):639-44. Epub 2021/01/19. doi:
651 10.1038/s41586-021-03207-w. PubMed PMID: 33461210.
- 652 34. Muecksch F, Weisblum Y, Barnes CO, Schmidt F, Schaefer-Babajew D, Wang Z, et al.
653 Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and
654 resilience to viral escape mutations. *Immunity*. 2021;54(8):1853-68 e7. Epub 2021/08/01. doi:
655 10.1016/j.immuni.2021.07.008. PubMed PMID: 34331873; PubMed Central PMCID:
656 PMC8323339.
- 657 35. Kim W, Zhou JQ, Horvath SC, Schmitz AJ, Sturtz AJ, Lei T, et al. Germinal centre-driven
658 maturation of B cell response to mRNA vaccination. *Nature*. 2022;604(7904):141-5. Epub
659 2022/02/16. doi: 10.1038/s41586-022-04527-1. PubMed PMID: 35168246.

- 660 36. Turner JS, O'Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ, et al. SARS-CoV-2
661 mRNA vaccines induce persistent human germinal centre responses. *Nature*.
662 2021;596(7870):109-13. Epub 2021/06/29. doi: 10.1038/s41586-021-03738-2. PubMed
663 PMID: 34182569; PubMed Central PMCID: PMC8935394.
- 664 37. Muecksch F, Wang Z, Cho A, Gaebler C, Ben Tanfous T, DaSilva J, et al. Increased
665 Memory B Cell Potency and Breadth After a SARS-CoV-2 mRNA Boost. *Nature*. 2022. Epub
666 2022/04/22. doi: 10.1038/s41586-022-04778-y. PubMed PMID: 35447027.
- 667 38. Yu J, Collier AY, Rowe M, Mardas F, Ventura JD, Wan H, et al. Neutralization of the
668 SARS-CoV-2 Omicron BA.1 and BA.2 Variants. *N Engl J Med*. 2022;386(16):1579-80. Epub
669 2022/03/17. doi: 10.1056/NEJMc2201849. PubMed PMID: 35294809; PubMed Central
670 PMCID: PMC9006770.
- 671 39. Evans JP, Zeng C, Qu P, Faraone J, Zheng YM, Carlin C, et al. Neutralization of SARS-
672 CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2. *Cell Host Microbe*. 2022. Epub
673 2022/05/09. doi: 10.1016/j.chom.2022.04.014. PubMed PMID: 35526534; PubMed Central
674 PMCID: PMC9035359.
- 675 40. Willett BJ, Kurshan A, Thakur N, Newman J, Manali M, Tyson G, et al. Distant antigenic
676 properties of the SARS-CoV-2 Omicron lineages BA.4 and BA.5. *bioRxiv*. 2022. doi:
677 10.1101/2022.05.25.493397.
- 678 41. Hachmann NP. Neutralization Escape by the SARS-CoV-2 Omicron Variants BA.2.12.1
679 and BA.4/BA.5. *medRxiv*. 2022. doi: 10.1101/2022.05.16.22275151.
- 680 42. Qu P, Faraone J, Evans JP, Zou X, Zheng YM, Carlin C, et al. Neutralization of the SARS-
681 CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants. *N Engl J Med*. 2022. Epub 2022/06/16. doi:
682 10.1056/NEJMc2206725. PubMed PMID: 35704428.
- 683 43. Khan K, Karim F, Cele S, Reedoy K, San JE, Lustig G, et al. Omicron infection enhances
684 Delta antibody immunity in vaccinated persons. *Nature*. 2022. Epub 2022/05/07. doi:
685 10.1038/s41586-022-04830-x. PubMed PMID: 35523247.
- 686 44. Kaku CI, Bergeron AJ, Ahlm C, Normark J, Sakharkar M, Forsell MNE, et al. Recall of
687 pre-existing cross-reactive B cell memory following Omicron BA.1 breakthrough infection. *Sci*
688 *Immunol*. 2022:eabq3511. Epub 2022/05/14. doi: 10.1126/sciimmunol.abq3511. PubMed
689 PMID: 35549299; PubMed Central PMCID: PMC9097882.
- 690 45. Richardson SI, Madzorera VS, Spencer H, Manamela NP, van der Mescht MA, Lambson
691 BE, et al. SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions
692 in previously vaccinated, but not unvaccinated, individuals. *Cell Host Microbe*. 2022. Epub
693 2022/04/19. doi: 10.1016/j.chom.2022.03.029. PubMed PMID: 35436444; PubMed Central
694 PMCID: PMC8947963.
- 695 46. Ying B, Scheaffer SM, Whitener B, Liang CY, Dmytrenko O, Mackin S, et al. Boosting
696 with variant-matched or historical mRNA vaccines protects against Omicron infection in mice.
697 *Cell*. 2022;185(9):1572-87 e11. Epub 2022/04/23. doi: 10.1016/j.cell.2022.03.037. PubMed
698 PMID: 35452622; PubMed Central PMCID: PMC8958157.
- 699 47. Nutalai R, Zhou D, Tuekprakhon A, Ginn HM, Supasa P, Liu C, et al. Potent cross-
700 reactive antibodies following Omicron breakthrough in vaccinees. *Cell*. 2022;185(12):2116-31
701 e18. Epub 2022/06/07. doi: 10.1016/j.cell.2022.05.014. PubMed PMID: 35662412.
- 702 48. Tuekprakhon A, Nutalai R, Djokaite-Guraliuc A, Zhou D, Ginn HM, Selvaraj M, et al.
703 Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. *Cell*.
704 2022. Epub 2022/07/01. doi: 10.1016/j.cell.2022.06.005. PubMed PMID: 35772405.

- 705 49. Reynolds CJ, Pade C, Gibbons JM, Otter AD, Lin KM, Munoz Sandoval D, et al. Immune
706 boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. *Science*.
707 2022:eabq1841. Epub 2022/06/15. doi: 10.1126/science.abq1841. PubMed PMID: 35699621.
- 708 50. Skowronski DM, Febriani Y, Ouakki M, Setayeshgar S, El Adam S, Zou M, et al. Two-
709 dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals:
710 test-negative design studies from British Columbia and Quebec, Canada. *Clin Infect Dis*. 2022.
711 Epub 2022/04/20. doi: 10.1093/cid/ciac290. PubMed PMID: 35438175; PubMed Central
712 PMCID: PMCPMC9047203.
- 713 51. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-
714 dose administration and the influence of the timing of the booster dose on immunogenicity
715 and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised
716 trials. *Lancet*. 2021;397(10277):881-91. Epub 2021/02/23. doi: 10.1016/S0140-
717 6736(21)00432-3. PubMed PMID: 33617777; PubMed Central PMCID: PMCPMC7894131.
- 718 52. Hall VG, Ferreira VH, Wood H, Ierullo M, Majchrzak-Kita B, Manguiat K, et al. Delayed-
719 interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces
720 robust T cell responses. *Nat Immunol*. 2022;23(3):380-5. Epub 2022/02/05. doi:
721 10.1038/s41590-021-01126-6. PubMed PMID: 35115679.
- 722 53. Pickering S, Betancor G, Galao RP, Merrick B, Signell AW, Wilson HD, et al. Comparative
723 assessment of multiple COVID-19 serological technologies supports continued evaluation of
724 point-of-care lateral flow assays in hospital and community healthcare settings. *PLoS Pathog*.
725 2020;16(9):e1008817. Epub 2020/09/25. doi: 10.1371/journal.ppat.1008817. PubMed PMID:
726 32970782; PubMed Central PMCID: PMCPMC7514033.
- 727 54. Dupont L, Snell LB, Graham C, Seow J, Merrick B, Lechmere T, et al. Neutralizing
728 antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants
729 of concern. *Nat Microbiol*. 2021;6(11):1433-42. Epub 2021/10/17. doi: 10.1038/s41564-021-
730 00974-0. PubMed PMID: 34654917; PubMed Central PMCID: PMCPMC8556155.
- 731 55. Grehan K, Ferrara F, Temperton N. An optimised method for the production of MERS-
732 CoV spike expressing viral pseudotypes. *MethodsX*. 2015;2:379-84. Epub 2015/11/21. doi:
733 10.1016/j.mex.2015.09.003. PubMed PMID: 26587388; PubMed Central PMCID:
734 PMCPMC4625112.
- 735 56. Thompson CP, Grayson NE, Paton RS, Bolton JS, Lourenco J, Penman BS, et al.
736 Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in
737 Scottish blood donors between March and May 2020. *Euro Surveill*. 2020;25(42). Epub
738 2020/10/24. doi: 10.2807/1560-7917.ES.2020.25.42.2000685. PubMed PMID: 33094713;
739 PubMed Central PMCID: PMCPMC7651873.
- 740
- 741
- 742